Open AccessAbstract CT240: A phase I clinical trial to study the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies
Author(s) -
Ana Tari Ashizawa,
Locke J. Bryan,
William Wierda
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct240
Subject(s) - medicine , lymphoma , pharmacokinetics , cancer , pharmacodynamics , chronic lymphocytic leukemia , in vivo , oncology , bleomycin , cancer research , pharmacology , chemotherapy , leukemia , biology , microbiology and biotechnology